Summary of Cost-effectiveness Estimates by Health Condition and Perspective
| . | Health Conditions . | ||||||
|---|---|---|---|---|---|---|---|
| BPD or CLD . | CHD . | Healthy . | Preterm . | Preterm With BPD or CLD . | Preterm With Risk Factors . | Other Risk Factorsa . | |
| Payer perspective | |||||||
| No. estimates | 6 | 10 | 6 | 22 | 4 | 14 | 4 |
| ICER (minimum) | 3984 | 9837 | Dominant | 5188 | 12 653 | 177 | Dominant |
| ICER (maximum) | 40 036 | 139 051 | 148 205 | 791 265 | 111 171 | 169 103 | 560 792 |
| Proportion of estimates’ CE <$50 000 per QALY | 1.00 | 0.80 | 0.67 | 0.86 | 0.75 | 0.79 | 0.50 |
| Proportion of estimates’ CE <$100 000 per QALY | 1.00 | 0.90 | 0.67 | 0.86 | 0.75 | 0.86 | 0.50 |
| Proportion of estimates’ CE <$200 000 per QALY | 1.00 | 1.00 | 1.00 | 0.91 | 1.00 | 1.00 | 0.75 |
| Societal perspective | |||||||
| No. estimates | 1 | 8 | 6 | 23 | 3 | 6 | 2 |
| ICER (minimum) | 23 469 | Dominant | Dominant | Dominant | 15 779 | 18 041 | Dominant |
| ICER (maximum) | 23 469 | 176.749 | 145 903 | 2 526 203 | 116 573 | 522 514 | Dominant |
| Proportion of estimates’ CE <$50 000 per QALY | 1.00 | 0.63 | 0.67 | 0.43 | 0.67 | 0.33 | 1.00 |
| Proportion of estimates’ CE <$100 000 per QALY | 1.00 | 0.63 | 0.83 | 0.48 | 0.67 | 0.67 | 1.00 |
| Proportion of estimates’ CE <$200 000 per QALY | 1.00 | 1.00 | 1.00 | 0.52 | 1.00 | 0.67 | 1.00 |
| . | Health Conditions . | ||||||
|---|---|---|---|---|---|---|---|
| BPD or CLD . | CHD . | Healthy . | Preterm . | Preterm With BPD or CLD . | Preterm With Risk Factors . | Other Risk Factorsa . | |
| Payer perspective | |||||||
| No. estimates | 6 | 10 | 6 | 22 | 4 | 14 | 4 |
| ICER (minimum) | 3984 | 9837 | Dominant | 5188 | 12 653 | 177 | Dominant |
| ICER (maximum) | 40 036 | 139 051 | 148 205 | 791 265 | 111 171 | 169 103 | 560 792 |
| Proportion of estimates’ CE <$50 000 per QALY | 1.00 | 0.80 | 0.67 | 0.86 | 0.75 | 0.79 | 0.50 |
| Proportion of estimates’ CE <$100 000 per QALY | 1.00 | 0.90 | 0.67 | 0.86 | 0.75 | 0.86 | 0.50 |
| Proportion of estimates’ CE <$200 000 per QALY | 1.00 | 1.00 | 1.00 | 0.91 | 1.00 | 1.00 | 0.75 |
| Societal perspective | |||||||
| No. estimates | 1 | 8 | 6 | 23 | 3 | 6 | 2 |
| ICER (minimum) | 23 469 | Dominant | Dominant | Dominant | 15 779 | 18 041 | Dominant |
| ICER (maximum) | 23 469 | 176.749 | 145 903 | 2 526 203 | 116 573 | 522 514 | Dominant |
| Proportion of estimates’ CE <$50 000 per QALY | 1.00 | 0.63 | 0.67 | 0.43 | 0.67 | 0.33 | 1.00 |
| Proportion of estimates’ CE <$100 000 per QALY | 1.00 | 0.63 | 0.83 | 0.48 | 0.67 | 0.67 | 1.00 |
| Proportion of estimates’ CE <$200 000 per QALY | 1.00 | 1.00 | 1.00 | 0.52 | 1.00 | 0.67 | 1.00 |
All ICERs are reported in 2017 USDs per QALY. CE, cost-effective.
Cystic fibrosis, major risk factors (chronological age <10 wk at beginning of RSV season [being born during first 10 wk of the season], school-aged siblings, and day care attendance), and minor risk factors (mother smoking during pregnancy and male sex).